Pharmacokinetics of four different brands of colistimethate and formed colistin in rats

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 10, 2013, Pages 2311-2317

  He, Hui ^a,d   Li, Ji Chang ^a,b   Nation, Roger L ^a   Jacob, Jovan ^a   Chen, Gong ^a   Lee, Hee Ji ^a   Tsuji, Brian T ^c   Thompson, Philip E ^a   Roberts, Kade ^a   Velkov, Tony ^a   Li, Jian ^a  

^a MONASH UNIVERSITY   (Australia)

^b NORTHEAST AGRICULTURAL UNIVERSITY   (China)

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY OF TENNESSEE COLLEGE OF PHARMACY   (United States)

Author keywords

Colistin base activity; Elemental analysis; HPLC; Intravenous administration

Indexed keywords

COLISTIMETHATE; COLISTIN;

AREA UNDER THE CURVE; ARTICLE; BLOOD; CHEMICAL COMPOSITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; RAT;

COLISTIN BASE ACTIVITY; ELEMENTAL ANALYSIS; HPLC; INTRAVENOUS ADMINISTRATION;

ADMINISTRATION, INTRAVENOUS; ANIMALS; ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLISTIN; ELEMENTS; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84884261348     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt207     Document Type: Article

References (29)

1. Infectious Diseases Society of America. The 10×'20 Initiative: Pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010; 50: 1081-3.
2. Payne DJ,Gwynn MN,Holmes DJ et al. Drugs forbadbugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007; 6: 29-40.
3. Talbot GH, Bradley J, Edwards JE Jr et al. Bad bugs need drugs: an update on the development pipeline fromthe Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006; 42: 657-68.
4. Landman D, Georgescu C, Martin DA et al. Polymyxins revisited. Clin Microbiol Rev 2008; 21: 449-65.
5. Li J, Nation RL, Turnidge JD et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006; 6: 589-601.
6. Bergen PJ, Landersdorfer CB, Zhang J et al. Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new? Diagn Microbiol Infect Dis 2012; 74: 213-23.
7. Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis 2009; 22: 535-43.
8. Decolin D, Leroy P, Nicolas A et al. Hyphenated liquid chromatographic method for the determination of colistin residues in bovine tissues. J Chromatogr Sci 1997; 35: 557-64.
9. Li J, Nation RL, Milne RW et al. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005; 25: 11-25.
10. Bergen PJ, Li J, Rayner CR et al. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50: 1953-8.
11. Li J, Milne RW, Nation RL et al. Stability of colistin and colistin methanesulfonate in aqueous media and plasma studied by highperformance liquid chromatography. Antimicrob Agents Chemother 2003; 47: 1364-70.
12. Wallace SJ, Li J, Rayner CR et al. Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients. Antimicrob Agents Chemother 2008; 52: 3047-51.
13. Li J, Milne RW, Nation RL et al. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 2004; 53: 837-40.
14. Marchand S, Lamarche I, Gobin P et al. Dose-ranging pharmacokinetics of colistin methanesulphonate (CMS) and colistin in rats following single intravenous CMS doses. J Antimicrob Chemother 2010; 65: 1753-8.
15. Li J, Coulthard K, Milne R et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 2003; 52: 987-92.
16. Plachouras D, Karvanen M, Friberg LE et al. Population pharmacokinetic analysis of colistin methanesulphonate and colistin after intravenous administration in critically ill patients with Gram-negative bacterial infections. Antimicrob Agents Chemother 2009; 53: 3430-6.
17. Couet W, Gregoire N, Gobin P et al. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin Pharmacol Ther 2011; 89: 875-9.
18. Marchand S, Frat JP, Petitpas F et al. Removal of colistin during intermittent haemodialysis in two critically ill patients. J Antimicrob Chemother 2010; 65: 1836-7.
19. Mohamed AF, Karaiskos I, Plachouras D et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 2012; 56: 4241-9.
20. Karvanen M, Plachouras D, Friberg LE et al. Colistin methanesulphonate and colistin pharmacokinetics in critically ill patients receiving continuous veno-venous hemodiafiltration (CVVHDF). Antimicrob Agents Chemother 2013; 57: 668-71.
21. Garonzik SM, Li J, Thamlikitkul V et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55: 3284-94.
22. Li J, Nation RL, Turnidge JD. Defining the dosage units for colistin methanesulfonate: urgent need for international harmonization. Antimicrob Agents Chemother 2006; 50: 4231.
23. Institute for Safe Medication Practices. Warning! Dosing confusion with colistimethate for injection. http://www.ashp.org/DocLibrary/Policy/ PatientSafety/NANAlert-Colistimethatesodium.aspx (24 April 2013, date last accessed).
24. Kirsten WJ. Organic Elemental Analysis. New York: Academic Press, 1983.
25. Dudhani RV, NationRL, Li J. Evaluating the stability of colistinand colistin methanesulphonate in human plasma under different conditions of storage. J Antimicrob Chemother 2010; 65: 1412-5.
26. Li J, Milne RW, Nation RL et al. Asimplemethod for the assayof colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2001; 761: 167-75.
27. Li J, Milne RW, Nation RL et al. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob Agents Chemother 2002; 46: 3304-7.
28. Cao G, Ali FE, Chiu F et al. Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxinB inhumanplasma. J AntimicrobChemother 2008;62: 1009-14.
29. Li J, Milne RW, Nation RL et al. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother 2003; 47: 1766-70.